The Pharmacist's Role in Paving the Treatment Success Pathway for Schizophrenia - Patient Follow-Up

The Pharmacist's Role in Paving the Treatment Success Pathway for Schizophrenia
Launch Date:
January 30, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:


Relevant Terms:


Roger W. Sommi, PharmD, FCCP, BCPP

Roger W. Sommi, PharmD, FCCP, BCPP
Professor of Pharmacy Practice & Administration and Psychiatry
UMKC Schools of Pharmacy and Medicine
Kansas City, MO

Dr. Sommi is Professor at the UMKC School of Pharmacy - Department of Pharmacy Practice, with a cross appointment in the Department of Psychiatry. He is also Research Director at the Psychopharmacy Research and Education Program at the Center for Behavioral Medicine (formerly Western Missouri Mental Health Center). He received his bachelor of science degree in Pharmacy from the University of Wisconsin at Madison, Doctor of Pharmacy the University of Utah, Residency in Hospital Pharmacy at the University of Utah Hospital and Fellowship in Psychopharmacy at the University of Texas at Austin. He is board certified in Psychiatric Pharmacy Practice by the Board of Pharmaceutical Specialties, Fellow of the American College of Clinical Pharmacy and is Past President of the College of Psychiatric and Neurologic Pharmacists.
His area of research interest is primarily in outcomes associated with drug treatment of schizophrenia and other psychiatric disorders. His practice is primarily associated with the ongoing projects in the research program. He is a consultant with several community mental health centers, and he is also involved with the local Kansas City NAMI as an instructor in the Crisis Intervention Team training program for local law enforcement agencies.
Dr. Sommi has received grant support from or is a consultant to the following: AstraZeneca, Boots, Bristol- Myers Squibb, SmithKlineBeecham, Hoescht Marion Roussel, Forest, Janssen, Eli Lilly, Merck, NIMH, Ortho-McNeil Janssen, Otsuka, Pfizer, Sanofi-aventis, Shire, Solvay, Sunovion, Novartis, Upjohn and Wyeth-Ayerst.

Dawn I. Velligan, PhD

Dawn I. Velligan, PhD
Professor and Co-director of the Division of Schizophrenia and Related Disorders
Department of Psychiatry
University of Texas Health Science Center at San Antonio
San Antonio, TX

Dr. Dawn Velligan is a Professor in the Department of Psychiatry and Chief of the Division of Schizophrenia and Related Disorders at the University of Texas Health Science Center at San Antonio. She received her training in clinical psychology at the University of California and Mental Health Clinical Research Center for Schizophrenia in Los Angeles. In 1989, Dr. Velligan moved to Texas to assist in the development of a psychosis treatment and research unit. Dr. Velligan's internationally recognized research program focuses on the development and testing of psychosocial treatments to improve adherence to medication and outcomes in schizophrenia. She developed Cognitive Adaptation Training (CAT), a unique treatment system designed to bypass the cognitive impairments observed in schizophrenia and to improve functional outcomes. Dr. Velligan is author of numerous publications in high impact journals and she has received grant funding from the National Institute of Health and The National Alliance for Research on Schizophrenia and Depression, as well as industry and private foundations. Dr. Velligan frequently serves as a consultant to industry and scientific investigators in the areas of symptom assessment, cognition and outcomes.

Peter Weiden, MD

Peter Weiden, MD
Professor of Psychiatry
University of Illinois Medical Center
Chicago, IL

Dr. Peter J. Weiden is Professor of Psychiatry at the University of Illinois Medical Center in Chicago.
Known for his work on patient and family education addressing the treatment of psychosis, much of Dr. Weiden's career has focused on improving clinical outcomes for patients with schizophrenia. His research has focused on bridging psychopharmacology and public health issues in the treatment of schizophrenia, and he has a particular interest in the use of cognitive behavioral therapy (CBT)-type interventions for individuals with psychotic disorders.
A frequent contributor to the medical literature, Dr. Weiden has authored or coauthored more than 150 journal articles as well as a number of books and practice guidelines. He has published extensively on the topic of nonadherence with antipsychotic medications. He serves on the editorial board of Clinical Psychiatry News and is a contributing editor for Journal of Practical Psychiatry and Behavioral Health. He is also a reviewer for a number of peer-reviewed publications.
Dr. Weiden has received several awards from advocacy groups and was named an Exemplary Psychiatrist on three separate occasions by the National Alliance on Mental Illness (NAMI). Dr. Weiden's book, Breakthroughs in Antipsychotic Medications: A Guide for Patients, Families, and Clinicians (WW Norton & Co.), received the Ken Johnson Memorial Book Award in 2000 as one of the most outstanding books in mental health. For his research on relapse prevention, he received NAMI's Judith Silver Young Scientist Award in 1996. He has been listed in the "Best Doctors in New York" issue of New York Magazine.
Active in many professional associations, Dr. Weiden is a member of the American Psychiatric Association, the International CBT for Psychosis Working Group, and the Academy of Cognitive Therapy. He also serves on NAMI's Scientific Advisory Board.
Dr. Weiden earned his bachelor of arts degree in Chemistry from Swarthmore College in Pennsylvania and his medical degree from the State University of New York at Stony Brook. He completed his psychiatric residency at the Payne Whitney Clinic-New York Hospital and a psychiatric epidemiology fellowship at the Mailman School of Public Health of Columbia University in New York City.
1. Evaluate important differences in safety, efficacy, pharmacokinetics (PK), and adherence data for the agents used in the long-term maintenance of schizophrenia.
2. Examine healthcare decision-making and motivational barriers among schizophrenia patients and healthcare providers.
3. Analyze and implement interventions among schizophrenia patients and other HCPs that will improve appropriate access to, and use of, antipsychotic medication, including use of LAIs.

Faculty Disclosures

  • Roger W. Sommi, PharmD, FCCP, BCPP, has affiliations with Otsuka, Merck, Sunovion, and Takeda (Speaker's Bureau); Otsuka, Janssen, and NIH (Research).
  • Dawn I. Velligan, MD, has affiliations with Genentech, Amgen, Abbvie, Otsuka, Lundbeck, and Janssen (Advisory); Genentech and Amgen (Research).
  • Peter J. Weiden, MD, has affiliations with Delpor, Johnson & Johnson (Janssen), Genentech, Roche, Lundbeck, Otsuka, Novartis, Reckitt Benckiser Pharmaceuticals, and Sunovion (Consulting); Johnson & Johnson (Janssen), Genentech, Roche, Lundbeck, Otsuka, Novartis, and Sunovion (Speaker's Bureau); Johnson & Johnson (Janssen), Genentech, Roche, Neurocrine, Novartis, and Sunovion (Research).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CPE activity:

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Cynthia M. Kunzer, CMP, has no affiliations with commercial interests to disclose.
The College of Psychiatric and Neurologic Pharmacists
  • Mary C. Borovicka, PharmD, BCPS, BCPP, has no affiliations with commercial interests to disclose.
  • Brenda Schimenti, MS, has no affiliations with commercial interests to disclose.
This educational activity does not contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA).

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of RMEI, CPNP, Otsuka and Lundbeck. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.


The College of Psychiatric and Neurologic Pharmacists (CPNP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE:  0284-9999-14-053-H01-P
Credits:  1.0 Contact Hour of ACPE Credit 
Type of Activity:  Application
Estimated time to complete:  60 minutes
Medium: Internet

There is no fee for this educational activity.

This activity is jointly sponsored by RMEI, LLC and The College of Psychiatric and Neurologic Pharmacists. RMEI gratefully acknowledges an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck in support of this CPE activity.

By reviewing the course content and successfully completing the post-test and evaluation, pharmacists are entitled to receive 1.0 Contact Hour of ACPE Credit. A transcript of credit will be available to print from your user history page with reporting to CPE Monitor to occur within one business day.
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Pharmacists who successfully complete the post-test and evaluation will receive CPE credit. You must score with a 70% or higher on the post-test to receive credit for this activity. You will have two attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.